CYFRA 21-1: a suitable tumor marker in patients with head and neck cutaneous squamous cell carcinoma? 2019

Stefan A Rudhart, and Johannes D Schultz, and Francesca Gehrt, and Friederike L Pavel, and Richard Birk, and Melika Hoch, and Boris A Stuck, and Stephan Hoch
Department of Otolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.

OBJECTIVE The clinical significance of cytokeratin fraction 21-1 (CYFRA 21-1) for patients with head and neck cutaneous squamous cell carcinoma (CSCC) is unknown. Thus, the aim of the study was to evaluate the clinical value of CYFRA 21-1 in the context of treatment and follow-up for these patients. METHODS The clinical, histological and laboratory data of a total of 55 patients with the first diagnosis of head and neck cutaneous squamous cell carcinoma (T1-T4, N0-N2b, M0-1) between 2003 and 2017 were retrospectively analyzed. In 25 cases, the primary tumor could be treated successfully without residual or recurrent disease in the further course. The average follow-up period was 2.3 years. In all patients, pretherapeutic determination of CYFRA 21-1 was performed using the ECLIA test kit. The cut-off value was set at 3.3 ng/ml. RESULTS In 18 patients (32.7%), regional recurrence was found in the course of treatment. Distant metastases could be observed in two patients (3.6%). In these cases, no significant increase of CYFRA 21-1 blood concentration was detected at the time of recurrence/metastasis. At the time of the first diagnosis, the mean value of CYFRA 21-1 blood concentration was 2.4 ng/ml; and in cases of regional recurrence or distant metastases, the initial mean CYFRA 21-1 concentration was 2.0 ng/ml. There was no statistically significant relationship between CYFRA 21-1 blood concentration and analyzed tumor characteristics. CONCLUSIONS According to current knowledge, the tumor marker CYFRA 21-1 is not clinically significant for treatment and follow-up of patients with head and neck CSCC.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D005260 Female Females
D006258 Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) Cancer of Head and Neck,Head Cancer,Head Neoplasm,Head and Neck Cancer,Head and Neck Neoplasm,Neck Cancer,Neck Neoplasm,Neck Neoplasms,Neoplasms, Upper Aerodigestive Tract,UADT Neoplasm,Upper Aerodigestive Tract Neoplasm,Upper Aerodigestive Tract Neoplasms,Cancer of Head,Cancer of Neck,Cancer of the Head,Cancer of the Head and Neck,Cancer of the Neck,Head Neoplasms,Head, Neck Neoplasms,Neoplasms, Head,Neoplasms, Head and Neck,Neoplasms, Neck,UADT Neoplasms,Cancer, Head,Cancer, Neck,Cancers, Head,Cancers, Neck,Head Cancers,Neck Cancers,Neoplasm, Head,Neoplasm, Neck,Neoplasm, UADT,Neoplasms, UADT
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077195 Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer. HNSCC,Head And Neck Squamous Cell Carcinomas,Hypopharyngeal Squamous Cell Carcinoma,Laryngeal Squamous Cell Carcinoma,Oral Cavity Squamous Cell Carcinoma,Oral Squamous Cell Carcinoma,Oral Squamous Cell Carcinomas,Oral Tongue Squamous Cell Carcinoma,Oropharyngeal Squamous Cell Carcinoma,Squamous Cell Carcinoma of Larynx,Squamous Cell Carcinoma of the Larynx,Squamous Cell Carcinoma of the Mouth,Squamous Cell Carcinoma of the Nasal Cavity,Carcinoma, Squamous Cell of Head and Neck,Head and Neck Squamous Cell Carcinoma,Squamous Cell Carcinoma of the Head and Neck,Squamous Cell Carcinoma, Head And Neck
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000359 Aftercare The care and treatment of a convalescent patient, especially that of a patient after surgery. After Care,After-Treatment,Follow-Up Care,Postabortal Programs,Postabortion,After Treatment,After-Treatments,Care, Follow-Up,Cares, Follow-Up,Follow Up Care,Follow-Up Cares,Postabortal Program,Program, Postabortal,Programs, Postabortal

Related Publications

Stefan A Rudhart, and Johannes D Schultz, and Francesca Gehrt, and Friederike L Pavel, and Richard Birk, and Melika Hoch, and Boris A Stuck, and Stephan Hoch
October 2005, The Annals of otology, rhinology, and laryngology,
Stefan A Rudhart, and Johannes D Schultz, and Francesca Gehrt, and Friederike L Pavel, and Richard Birk, and Melika Hoch, and Boris A Stuck, and Stephan Hoch
February 1995, Archives of otolaryngology--head & neck surgery,
Stefan A Rudhart, and Johannes D Schultz, and Francesca Gehrt, and Friederike L Pavel, and Richard Birk, and Melika Hoch, and Boris A Stuck, and Stephan Hoch
January 1997, ORL; journal for oto-rhino-laryngology and its related specialties,
Stefan A Rudhart, and Johannes D Schultz, and Francesca Gehrt, and Friederike L Pavel, and Richard Birk, and Melika Hoch, and Boris A Stuck, and Stephan Hoch
February 1998, Clinical otolaryngology and allied sciences,
Stefan A Rudhart, and Johannes D Schultz, and Francesca Gehrt, and Friederike L Pavel, and Richard Birk, and Melika Hoch, and Boris A Stuck, and Stephan Hoch
January 1998, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus,
Stefan A Rudhart, and Johannes D Schultz, and Francesca Gehrt, and Friederike L Pavel, and Richard Birk, and Melika Hoch, and Boris A Stuck, and Stephan Hoch
November 2017, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus,
Stefan A Rudhart, and Johannes D Schultz, and Francesca Gehrt, and Friederike L Pavel, and Richard Birk, and Melika Hoch, and Boris A Stuck, and Stephan Hoch
July 1997, Nihon Jibiinkoka Gakkai kaiho,
Stefan A Rudhart, and Johannes D Schultz, and Francesca Gehrt, and Friederike L Pavel, and Richard Birk, and Melika Hoch, and Boris A Stuck, and Stephan Hoch
September 2013, European review for medical and pharmacological sciences,
Stefan A Rudhart, and Johannes D Schultz, and Francesca Gehrt, and Friederike L Pavel, and Richard Birk, and Melika Hoch, and Boris A Stuck, and Stephan Hoch
May 1997, Cancer,
Stefan A Rudhart, and Johannes D Schultz, and Francesca Gehrt, and Friederike L Pavel, and Richard Birk, and Melika Hoch, and Boris A Stuck, and Stephan Hoch
June 2010, Anticancer research,
Copied contents to your clipboard!